Literature DB >> 22577221

Widespread abnormality of the γ-aminobutyric acid-ergic system in Tourette syndrome.

Alicja Lerner1, Anto Bagic, Janine M Simmons, Zoltan Mari, Omer Bonne, Ben Xu, Diane Kazuba, Peter Herscovitch, Richard E Carson, Dennis L Murphy, Wayne C Drevets, Mark Hallett.   

Abstract

Dysfunction of the γ-aminobutyric acid-ergic system in Tourette syndrome may conceivably underlie the symptoms of motor disinhibition presenting as tics and psychiatric manifestations, such as attention deficit hyperactivity disorder and obsessive-compulsive disorder. The purpose of this study was to identify a possible dysfunction of the γ-aminobutyric acid-ergic system in Tourette patients, especially involving the basal ganglia-thalamo-cortical circuits and the cerebellum. We studied 11 patients with Tourette syndrome and 11 healthy controls. Positron emission tomography procedure: after injection of 20 mCi of [(11)C]flumazenil, dynamic emission images of the brain were acquired. Structural magnetic resonance imaging scans were obtained to provide an anatomical framework for the positron emission tomography data analysis. Images of binding potential were created using the two-step version of the simplified reference tissue model. The binding potential images then were spatially normalized, smoothed and compared between groups using statistical parametric mapping. We found decreased binding of GABA(A) receptors in Tourette patients bilaterally in the ventral striatum, globus pallidus, thalamus, amygdala and right insula. In addition, the GABA(A) receptor binding was increased in the bilateral substantia nigra, left periaqueductal grey, right posterior cingulate cortex and bilateral cerebellum. These results are consistent with the longstanding hypothesis that circuits involving the basal ganglia and thalamus are disinhibited in Tourette syndrome patients. In addition, the abnormalities in GABA(A) receptor binding in the insula and cerebellum appear particularly noteworthy based upon recent evidence implicating these structures in the generation of tics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22577221      PMCID: PMC3359755          DOI: 10.1093/brain/aws104

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  83 in total

1.  Functional neuroanatomy of Tourette syndrome. Limbic-motor interactions studied with FDG PET.

Authors:  B Stoetter; A R Braun; C Randolph; J Gernert; R E Carson; P Herscovitch; T N Chase
Journal:  Adv Neurol       Date:  1992

Review 2.  Positron emission tomography evaluation of dopamine D-2 receptors in adults with Tourette syndrome.

Authors:  H S Singer; D F Wong; J E Brown; J Brandt; L Krafft; E Shaya; R F Dannals; H N Wagner
Journal:  Adv Neurol       Date:  1992

Review 3.  The role of the amygdala in fear and anxiety.

Authors:  M Davis
Journal:  Annu Rev Neurosci       Date:  1992       Impact factor: 12.449

4.  Possible exacerbation of tics by androgenic steroids.

Authors:  J F Leckman; L Scahill
Journal:  N Engl J Med       Date:  1990-06-07       Impact factor: 91.245

5.  The functional neuroanatomy of Tourette's syndrome: an FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls.

Authors:  A R Braun; B Stoetter; C Randolph; J K Hsiao; K Vladar; J Gernert; R E Carson; P Herscovitch; T N Chase
Journal:  Neuropsychopharmacology       Date:  1993-12       Impact factor: 7.853

6.  PET studies of the presynaptic and postsynaptic dopaminergic system in Tourette's syndrome.

Authors:  N Turjanski; G V Sawle; E D Playford; R Weeks; A A Lammerstma; A J Lees; D J Brooks
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-06       Impact factor: 10.154

7.  Distribution of central omega 1 (benzodiazepine1) and omega 2 (benzodiazepine2) receptor subtypes in the monkey and human brain. An autoradiographic study with [3H]flunitrazepam and the omega 1 selective ligand [3H]zolpidem.

Authors:  T Dennis; A Dubois; J Benavides; B Scatton
Journal:  J Pharmacol Exp Ther       Date:  1988-10       Impact factor: 4.030

8.  Benzodiazepine receptor sites in the human brain: autoradiographic mapping.

Authors:  J Zezula; R Cortés; A Probst; J M Palacios
Journal:  Neuroscience       Date:  1988-06       Impact factor: 3.590

9.  The Yale Global Tic Severity Scale: initial testing of a clinician-rated scale of tic severity.

Authors:  J F Leckman; M A Riddle; M T Hardin; S I Ort; K L Swartz; J Stevenson; D J Cohen
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1989-07       Impact factor: 8.829

Review 10.  Steroid hormones and CNS sexual dimorphisms modulate symptom expression in Tourette's syndrome.

Authors:  B S Peterson; J F Leckman; L Scahill; F Naftolin; D Keefe; N J Charest; D J Cohen
Journal:  Psychoneuroendocrinology       Date:  1992-11       Impact factor: 4.905

View more
  66 in total

1.  Reduced GABAergic inhibition and abnormal sensory symptoms in children with Tourette syndrome.

Authors:  Nicolaas A J Puts; Ashley D Harris; Deana Crocetti; Carrie Nettles; Harvey S Singer; Mark Tommerdahl; Richard A E Edden; Stewart H Mostofsky
Journal:  J Neurophysiol       Date:  2015-06-03       Impact factor: 2.714

Review 2.  Abnormal neuronal activity in Tourette syndrome and its modulation using deep brain stimulation.

Authors:  Michal Israelashvili; Yocheved Loewenstern; Izhar Bar-Gad
Journal:  J Neurophysiol       Date:  2015-04-29       Impact factor: 2.714

Review 3.  What makes you tic? Translational approaches to study the role of stress and contextual triggers in Tourette syndrome.

Authors:  Sean C Godar; Marco Bortolato
Journal:  Neurosci Biobehav Rev       Date:  2016-12-08       Impact factor: 8.989

4.  Deep brain stimulation reduces Tic-related neural activity via temporal locking with stimulus pulses.

Authors:  Kevin W McCairn; Atsushi Iriki; Masaki Isoda
Journal:  J Neurosci       Date:  2013-04-10       Impact factor: 6.167

5.  Role of the sensorimotor cortex in Tourette syndrome using multimodal imaging.

Authors:  Sule Tinaz; Beth A Belluscio; Patrick Malone; Jan Willem van der Veen; Mark Hallett; Silvina G Horovitz
Journal:  Hum Brain Mapp       Date:  2014-07-15       Impact factor: 5.038

Review 6.  A Review and Update on Tourette Syndrome: Where Is the Field Headed?

Authors:  Aysegul Gunduz; Michael S Okun
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

7.  Similar striatal D2/D3 dopamine receptor availability in adults with Tourette syndrome compared with healthy controls: A [(11) C]-(+)-PHNO and [(11) C]raclopride positron emission tomography imaging study.

Authors:  Elia Abi-Jaoude; Barbara Segura; Ignacio Obeso; Sang Soo Cho; Sylvain Houle; Anthony E Lang; Pablo Rusjan; Paul Sandor; Antonio P Strafella
Journal:  Hum Brain Mapp       Date:  2015-03-18       Impact factor: 5.038

8.  Cefdinir for recent-onset pediatric neuropsychiatric disorders: a pilot randomized trial.

Authors:  Tanya K Murphy; E Carla Parker-Athill; Adam B Lewin; Eric A Storch; P Jane Mutch
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-10-09       Impact factor: 2.576

9.  Treatment of Tourette syndrome.

Authors:  Roger M Kurlan
Journal:  Neurotherapeutics       Date:  2014-01       Impact factor: 7.620

Review 10.  Genetic susceptibility and neurotransmitters in Tourette syndrome.

Authors:  Peristera Paschou; Thomas V Fernandez; Frank Sharp; Gary A Heiman; Pieter J Hoekstra
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.